Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

NSCLC, metastatic

1608 - Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung


09 Oct 2016


NSCLC, metastatic


Vamsidhar Velcheti


Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383


V. Velcheti1, T. Hida2, K.L. Reckamp3, J.C. Yang4, H. Nokihara5, P. Sachdev6, K. Feit6, T. Kubota7, T. Nakada7, C.E. Dutcus6, M. Ren6, T. Tamura8

Author affiliations

  • 1 Taussig Cancer Institute, Cleveland Clinic, 44195 - Cleveland/US
  • 2 Aichi Cancer Center Hospital, Oncology, Nagoya/JP
  • 3 City Of Hope, Hospital, Duarte/US
  • 4 National Taiwan University Hospital, and National Taiwan University Cancer Center, Taipei City/TW
  • 5 National Cancer, Center Hospital, 104-0045 - Tokyo/JP
  • 6 Eisai Co., Inc., 07677 - Woodcliff Lake/US
  • 7 Eisai Co., Ltd., Tokyo/JP
  • 8 Thoracic Center, St. Luke's International Hospital, 104-8560 - Tokyo/JP


Abstract 1608


Adenocarcinoma, a type of non-small cell lung carcinoma (NSCLC), is one of the most common forms of lung cancer. RET fusions activate RET kinase and occur in 1% to 2% of these pts. LN, a multikinase inhibitor whose targets include RET, may be a treatment option for pts with NSCLC.


This open label, phase 2 study enrolled pts with RET-positive lung adenocarcinoma. Pts received LN 24 mg/d in 28-d cycles until disease progression or unacceptable toxicity. Notably, pts may have received prior RET-targeted therapy. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR; complete response [CR] + partial response [PR] + stable disease [SD, ≥ 7 weeks]), clinical benefit rate (CBR; CR + PR + durable SD [≥23 weeks]), and safety.


25 Pts with RET-positive NSCLC enrolled (KIF5B-RET: 13, other RET fusion: 12). 15 (60%) had ≥2 prior lines of therapy, 7 (28%) had prior RET therapy, and only 2 (8%) had no prior therapy. 16 (64%) were never smokers, 1 (4%) current smoker, 7 (28%) former smokers and 1 (4%) unknown. Tumor shrinkage occurred in the majority of pts; ORR was 16% (confirmed PRs). DCR was 76%. The table shows efficacy data by previous RET therapy. Median duration of treatment was 16 weeks (range: 2–117). Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 23 (92%) pts. Of 3 fatal AEs, 1 was possibly related to LN (pneumonia). TEAEs requiring drug withdrawal, dose reduction, and dose interruption occurred in 5 (20%), 16 (64%), and 19 (76%) pts, respectively. The most common TEAEs included hypertension (68%), nausea (60%), decreased appetite (52%), diarrhea (52%), proteinuria (48%), and vomiting (44%).

Prior RET therapy All Pts n = 25
Yes n = 7 No n = 18
ORR,* n (%) 1 (14) 3 (17) 4 (16)
Median PFS (95% CI), months - - 7.3 (3.6–10.2)
Median OS (95% CI), months - - NE (5.8–NE)
DCR, n (%) 6 (86) 13 (72) 19 (76)
CBR, n (%) 4 (57) 8 (44) 12 (48)

CI, confidence interval; DCR, disease control rate defined as CR + PR + SD lasting ≥ 7 weeks; NE, not evaluable. * All confirmed PRs


LN showed promising clinical activity in pts with RET-positive NSCLC. For most pts, toxicities were manageable with dose modification. These results provide support for LN as a potential treatment for RET-positive NSCLC.

Clinical trial identification


Legal entity responsible for the study

Eisai Inc.


Eisai Inc.


V. Velcheti: Corporate-sponsored research: Merck Inc., Eisai, Genoptix Inc., Genentech, Altor Biosciences, Heat Biologics, Alkermes, Amgen, Nantomics, NanoVision Diagnostics. T. Hida: Corporate sponsored research- Eisai. K.L. Reckamp: Corporate-sponsored research: Eisai Inc., (clinical trial, to institution); editorial assistance. J.C. Yang: Advisory board for: Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, AstraZeneca, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, innopharma, Merrimack. H. Nokihara: Clinical trial-Eisai Inc. P. Sachdev, K. Feit, M. Ren: Employee of Eisai Inc. T. Kubota, T. Nakada: Employee of Eisai Co., Ltd., Tokyo Japan. C.E. Dutcus: Employee of Eisai Inc. T. Tamura: Received Honoraria from Eisai.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings